05.02.2013 Views

Bulletin 2011/35 - European Patent Office

Bulletin 2011/35 - European Patent Office

Bulletin 2011/35 - European Patent Office

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

(A61K) I.1(2)<br />

• Methods and compositions for the treatment<br />

of hyperlipidemia<br />

• Méthodes et compositions de traitement de<br />

l'hyperlipidémie<br />

(71) Institute of Medicinal Biotechnology, Chinese<br />

Academy of Medical Sciences, Tiantan Xili<br />

No 1, Beijing 100050, CN<br />

(72) Jiang, Jian-Dong, 100050, Beijing, CN<br />

Kong, Wei-Jia, 100050, Beijing, CN<br />

Zhao, Li-Xun, 100067, Beijing, CN<br />

Song, Dan-Qing, 100078, Beijing, CN<br />

Wei, Jing, 210006, Nanjing Beijing, CN<br />

(74) Walker, Ross Thomson, Forrester & Boehmert<br />

Pettenkoferstrasse 20-22, 80336<br />

München, DE<br />

(62) 05791957.3 / 1 796 666<br />

A61K 31/439 → (51) C07D 471/08<br />

A61K 31/44 → (51) C07D 213/82<br />

A61K 31/4433 → (51) C07D 213/82<br />

A61K 31/4439 → (51) A61K 31/421<br />

A61K 31/4439 → (51) C07D 213/82<br />

A61K 31/444 → (51) C07D 213/82<br />

A61K 31/445 → (51) C12N 15/09<br />

A61K 31/455 → (51) C07D 213/82<br />

A61K 31/4709 → (51) G01N 33/50<br />

A61K 31/4725 → (51) A61K 31/4375<br />

A61K 31/4745 → (51) C07D 471/04<br />

(51) A61K 31/496 (11) 2 361 626 A1<br />

A61K 31/517 A61P <strong>35</strong>/00<br />

A61K 31/404<br />

(25) En (26) En<br />

(21) 10184960.2 (22) 24.04.2004<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HU IE IT LI LU MC NL PL PT RO SE SI SK<br />

TR<br />

(27) 24.04.2004 EP 04729366<br />

(30) 29.04.2003 EP 03009587<br />

13.01.2004 EP 04000508<br />

21.01.2004 EP 04001171<br />

(54) • Kombinationspräparate zur Behandlung<br />

von Krankheiten, die Proliferation, Migration,<br />

Apoptosis oder Agiogenese der Myeloma<br />

Zellen umfassen<br />

• Combinations for the treatment of diseases<br />

involving cell proliferation, migration or<br />

apoptosis of myeloma cells, or angiogenesis<br />

• Combinaisons pour le traitement des<br />

maladies impliquant une prolifération cellulaire,<br />

migration ou apoptose des cellules<br />

de myélome, ou angiogenèse<br />

(71) BOEHRINGER INGELHEIM INTERNATIONAL<br />

GMBH, Binger Str. 173, 55216 Ingelheim am<br />

Rhein, DE<br />

(84) AT BE BG CH CY CZ DK EE ES FI FR GB GR<br />

HU IE IT LI LU MC NL PL PT RO SE SI SK TR<br />

(71) Boehringer Ingelheim Pharma GmbH & Co.<br />

KG, Binger Strasse 173, 55216 Ingelheim am<br />

Rhein, DE<br />

(84) DE<br />

(72) Hilberg, Frank, 1050, WIEN, AT<br />

Solca, Flavio, 1230, WIEN, AT<br />

Stefanic, Martin Friedrich, 88447,<br />

WARTHAUSEN, DE<br />

Baum, Anke, 2534, ALLAND, AT<br />

Munzert, Gerd, 89075, ULM, DE<br />

Europäisches <strong>Patent</strong>blatt<br />

<strong>European</strong> <strong>Patent</strong> <strong>Bulletin</strong><br />

<strong>Bulletin</strong> européen des brevets<br />

Van Meel, Jacobus, C.A., 2340, MÖDLING,<br />

AT<br />

(74) Hammann, Heinz, et al, Boehringer Ingelheim<br />

GmbH Corporate <strong>Patent</strong>s Binger Strasse 173,<br />

55216 Ingelheim am Rhein, DE<br />

(62) 04729366.7 / 1 622 619<br />

A61K 31/497 → (51) C07D 213/82<br />

A61K 31/501 → (51) C07D 213/82<br />

A61K 31/501 → (51) C07D 237/24<br />

A61K 31/506 → (51) C07D 213/82<br />

A61K 31/506 → (51) C07D 401/12<br />

A61K 31/513 → (51) C07H 19/073<br />

A61K 31/517 → (51) A61K 31/496<br />

A61K 31/519 → (51) A61K 9/00<br />

A61K 31/519 → (51) A61K 9/22<br />

A61K 31/5377 → (51) C07D 213/82<br />

A61K 31/5383 → (51) C07D 471/04<br />

A61K 31/55 → (51) C07D 213/82<br />

A61K 31/55 → (51) C07D 471/04<br />

A61K 31/551 → (51) C07D 213/82<br />

A61K 31/553 → (51) C07D 213/82<br />

A61K 31/554 → (51) C07D 471/04<br />

A61K 31/606 → (51) A61K 31/166<br />

A61K 31/661 → (51) C07F 9/09<br />

A61K 31/695 → (51) C07D 225/06<br />

A61K 31/70 → (51) C07H 19/06<br />

(51) A61K 31/7016 (11) 2 361 627 A2<br />

(25) Ko (26) En<br />

(21) 09822176.5 (22) 16.10.2009<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HR HU IE IS IT LI LT LU LV MC MK MT<br />

NL NO PL PT RO SE SI SK SM TR<br />

(86) KR 2009/005983 16.10.2009<br />

(87) WO 2010/047500 2010/17 29.04.2010<br />

(88) 19.08.2010<br />

(30) 20.10.2008 KR 20080102660<br />

(54) • ZUSAMMENSETZUNG ZUR PRÄVENTION<br />

ODER BEHANDLUNG VON AUGENKRANK-<br />

HEITEN<br />

• COMPOSITION FOR PREVENTION OR<br />

TREATMENT OF EYE DISEASES<br />

• COMPOSITION POUR PRÉVENTION OU<br />

TRAITEMENT DE MALADIES OCULAIRES<br />

(71) Benebiosis Co., Ltd., 911Ho, 923Ho KGIT<br />

Sangam Center 1-danji 1601 Sangda-dong<br />

Mapo-gu, Seoul 121-270, KR<br />

Sungkyunkwan University Foundation for<br />

Corporate Collaboration, 300, Cheoncheondong<br />

Jangan-gu Suwon-si, Gyeonggi-do<br />

440-746, KR<br />

(72) KANG, Seung Woo, Seoul 121-260, KR<br />

KIM, Cheorl-Ho, Daegu 706-014, KR<br />

KIM, Seok-Jo, Busan 604-767, KR<br />

(74) Winkler, Andreas Fritz Ernst, Forrester &<br />

Boehmert Pettenkoferstrasse 20-22, 80336<br />

München, DE<br />

97<br />

Anmeldungen<br />

Applications<br />

Demandes (<strong>35</strong>/<strong>2011</strong>) 31.08.<strong>2011</strong><br />

A61K 31/7048 → (51) C07H 9/02<br />

A61K 31/7052 → (51) C07H 9/02<br />

A61K 31/7088 → (51) C12N 15/09<br />

A61K 31/712 → (51) C07H 21/00<br />

(51) A61K 33/36 (11) 2 361 628 A1<br />

A61P <strong>35</strong>/00<br />

(25) En (26) En<br />

(21) 11165670.8 (22) 09.05.2006<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HU IE IS IT LI LT LU LV MC NL PL PT RO<br />

SE SI SK TR<br />

(30) 09.05.2005 PCT/EP2005/076071<br />

(54) • Pharmazeutische Zusammensetzungen mit<br />

Natrium-Meta-Arsenite zur Behandlung von<br />

Leukämie und Lymphom<br />

• Pharmaceutical compositions comprising<br />

of sodium meta-arsenite for use in the<br />

treatment of leukemia and lymphoma<br />

• Compositions pharmaceutiques comprenant<br />

la sodium meta-arsénit puor traiter la<br />

leucémie et le lymphome<br />

(71) Kominox, Inc., 1 Cayman Financial Centre<br />

36A Dr Roy's Drive, George Town, Grand<br />

Cayman KY1-1104, KY<br />

(72) Lee, Sang-Bong, 431-070, Kyonggi-do, KR<br />

Yang, Yong-Jin, 463-500, Kyonggi-do, KR<br />

(74) Sharples, Andrew John, et al, EIP Fairfax<br />

House 15 Fulwood Place, London WC1V<br />

6HU, GB<br />

(62) 06732912.8 / 1 885 380<br />

A61K <strong>35</strong>/12 → (51) A61F 2/06<br />

A61K <strong>35</strong>/12 → (51) C12N 5/0775<br />

A61K <strong>35</strong>/14 → (51) C12N 15/09<br />

A61K <strong>35</strong>/28 → (51) C12N 5/0775<br />

A61K <strong>35</strong>/28 → (51) C12N 5/078<br />

A61K <strong>35</strong>/28 → (51) C12N 5/10<br />

A61K <strong>35</strong>/60 → (51) A23L 1/30<br />

A61K 38/00 → (51) C12N 15/09<br />

A61K 38/00 → (51) C12Q 1/68<br />

A61K 38/00 → (51) G01N 33/566<br />

A61K 38/01 → (51) A61K 31/<strong>35</strong>3<br />

A61K 38/07 → (51) C07K 5/10<br />

(51) A61K 38/17 (11) 2 361 629 A1<br />

A61K 39/00 A61P 25/16<br />

(25) En (26) En<br />

(21) 11164647.7 (22) 31.10.2003<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HU IE IT LI LU MC NL PT RO SE SI SK<br />

TR<br />

(30) 01.11.2002 US 423012 P<br />

(54) • Prävention und Behandlung von synucleinopathischer<br />

Erkrankung<br />

• Prevention and treatment of synucleinopathic<br />

disease<br />

• Prévention et traitement d'une maladie<br />

synucleopathique<br />

(71) Elan Pharmaceuticals Inc., 800 Gateway<br />

Boulevard, South San Francisco, CA 94080,<br />

US<br />

The Regents of the University of California,<br />

1111 Franklin Street, Oakland, California<br />

94607, US

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!